World Journal of Pharmaceutical
and Medical Research

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical and Medical Research and Technology
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
ISSN 2455-3301
IMPACT FACTOR: 6.842

ICV : 78.6

World Journal of Pharmaceutical and Medical Research (WJPMR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Indian Science Publications , Cosmos Impact Factor , Research Bible, Fuchu, Tokyo. JAPAN , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , International Innovative Journal Impact Factor (IIJIF) , Scientific Journal Impact Factor (SJIF) , Global Impact Factor (In Process) , Digital Online Identifier-Database System (DOI-DS) , Science Library Index, Dubai, United Arab Emirates , Eurasian Scientific Journal Index (ESJI) , International Scientific Indexing, (ISI) UAE , IFSIJ Measure of Journal Quality , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

Abstract

LOW-DOSE ENZALUTAMIDE AS SECOND-LINE HORMONE THERAPY IN CASTRATION-RESISTANT PROSTATE CANCER - TWO CASES

Dr. K. Diakité*, Z. Dahbi, A. Groulier, J. Perrin, S. Hny and V. Vinh-Hung

ABSTRACT

Enzalutamide at a recommended dosage of 160 mg / day is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) by improving overall survival in chemo-naive patients but also in those who progressed under docetaxel. It is also indicated in locally advanced disease. We report two cases of good tolerance and clinical remission with low-dose enzalutamide.

[Full Text Article]    [Download Certificate]

Powered By WJPMR | All Right Reserved

WJPMR